We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Tes5.0

Tesamorelin Research

Mostly mechanism / observational

27 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Tesamorelin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 2004–2026 with a typical study size of 61 participants.

Based on 27 studies · 2 meta-analyses · 19 RCTs · 905 total participants

Confidence

High confidence

By outcome

Visceral fat & body compositionIn ART-treated HIV patients with excess abdominal fat, visceral adipose tissue fell ~15-18% vs placebo over 26-52 weeks (only shown in this population) · 26-52 weeks
Mostly mechanism / observational15 studies
Liver healthA Lancet HIV RCT found a ~37% relative reduction in hepatic fat fraction over 12 months (small trials in HIV patients, not an approved indication) · 6-12 months
Mostly mechanism / observational5 studies
Cognitive function
Mostly mechanism / observational3 studies
Safety profile
Mostly mechanism / observational3 studies
Glucose & metabolic
Too few graded studies2 studies

Steady research

8 studies in the last 5 years · Latest meta-analysis: 2026

200420152026

1Meta-Analysis2026

Ditta AM, Naeem RM, Sami MM, Abdul Rafey M, Ali H, Amjad MW · J Int Assoc Provid AIDS Care (2026)

Tesamorelin Research

Mostly mechanism / observational

Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.

Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol